C urrent guidelines propose out-of-office blood pressure measurement as the standard in the diagnosis and management of hypertension. 1-3 Self-measurement of the blood pressure at home offers several of the well-recognized advantages of the more complex approach of ambulatory monitoring. [4] [5] [6] The greater number of readings and the minimization of the white coat effect, observer bias, and measurement error all contribute to better diagnostic accuracy compared with office blood pressure measurement. Similar to visit-to-visit variability in clinic blood pressure, 7 multiple home blood pressure measurements 8-10 provide information on day-to-day blood pressure variability in the relatively controlled home environment.
Data Collection
Physicians and public health nurses instructed participants how to measure their home blood pressure using a validated oscillometric device (OMRON HEM 401C, Omron Healthcare Co Ltd, Kyoto, Japan). 13 Participants were asked to record their blood pressure for 4 weeks after ≥2 minutes of rest in the morning within 1 hour after awakening and, if applicable, before taking their blood pressure-lowering medications, and in the evening just before going to bed. 3 The first reading obtained on each occasion was used for analysis.
At public health centers, study nurses measured anthropometric characteristics. Body mass index was weight in kilograms divided by the square of height in meters. The nurses also administered questionnaires inquiring into each participant's medical history, intake of medications, and smoking and drinking habits. Venous blood samples were analyzed for total cholesterol and blood glucose. Diabetes mellitus was a fasting or random blood glucose level of ±7.0 or 11.1 mmol/L or the use of insulin or oral antidiabetic drugs. 14 Hypercholesterolemia was a serum level of ≥5.68 mmol/L or use of lipid-lowering agents. Previous cardiovascular disease included coronary heart disease, atrial fibrillation, and heart failure.
Follow-Up and Risk Assessment
We ascertained outcome until December 31, 2004, based on the Ohasama residents' registration cards, which in Japan provide access to social security and retirement benefits; the National Japanese Mortality Registry of causes of death; the Stroke Registration System of Iwate Prefecture; and questionnaires sent every 4 years to each participant. End points were all-cause and cardiovascular mortality and stroke events. Cardiovascular mortality included deaths from cerebrovascular and cardiac causes. Stroke events included, in addition to fatal events, nonfatal stroke but not transient ischemic attack. End points were adjudicated by checking the medical charts at Ohasama Hospital, where >90% of participants had regular health checkups.
Statistical Analysis
For database management and statistical analysis, we used the SAS system, version 9.3 (SAS Institute Inc, Cary, NC). We limited our analyses to systolic blood pressure, because this is the overriding risk factor in middle-aged and older people. 15 We used all of the available home readings of the self-measured blood pressure. We analyzed the morning and evening blood pressures separately, because previous studies showed that they have a different prognostic meaning. 5 In sensitivity analyses, we used 5 home readings in the morning and 5 in the evening (10 readings) according to European population studies 16 and the Japanese randomized trial. 17 For descriptive purposes, we computed the within-participant blood pressure variability from the SD and coefficient of variation. We based our analyses on VIM, difference between maximum minus minimum blood pressure (MMD), and average real variability (ARV). Coefficient of variation is the within-participant SD divided by the within-participant mean. VIM 7, 11 is SD divided by the mean to the power x . Power x is modeled as SD = a × mean x and was derived by nonlinear regression analysis as implemented in the PROC NLIN procedure of the SAS package. ARV is the average of the absolute differences between consecutive day blood pressure measurements. 18, 19 We compared means and proportions using the standard normal z test for large samples and the Fisher exact test, respectively. Kruskal-Wallis test was used to assess differences between quartiles of VIM. We plotted incidence rates by fourths of the blood pressure variability distribution while standardizing rates for sex and age by the direct method. In multivariable-adjusted Cox regression, we derived standardized relative hazard ratios that expressed the change in risk associated with 1-SD increase in mean blood pressure or in variability. Covariables were sex, age, body mass index, heart rate, smoking and drinking, diabetes mellitus, total cholesterol, history of cardiovascular disease, and treatment with antihypertensive drugs. For 608 participants without known alcohol use, we interpolated drinking status based on sex and age (continuous). We checked the proportional hazards assumption by testing the interaction terms between follow-up duration and the variable of interest. Finally, we applied the generalized R 2 statistic 20 to assess the additional risk explained in Cox regression by adding the indices of blood pressure variability to models already including the mean systolic blood pressure level and covariables. The formula for the calculation of generalized R 2 is as follows:
where n is the number of participants, ln L(X 2 ) and ln L(X 1 ) are the log likelihood statistics of the full model and the basic model, respectively, and χ 2 is the likelihood ratio chi-square.
Results

Baseline Characteristics
Of the 2421 participants, 656 (27.1%) were treated with antihypertensive drugs at baseline, 475 (19.6%) were current smokers, 219 (9.1%) had diabetes mellitus, and 635 (26.2%) had hypercholesterolemia. The median number of days with self-measured blood pressure readings available for analysis was 26 (interquartile range, 21 to 28) in the morning and 26 (interquartile range, 22 to 28) in the evening. The self-measured systolic blood pressure was 2.15 mm Hg (95% confidence interval [CI], 1.88-2.42 mm Hg; P<0.0001) higher in the morning than evening. In patients on antihypertensive drug treatment, this difference was to 3.55 mm Hg (95% CI, 2.91-4.18 mm Hg; P<0.0001). For the morning blood pressure, the VIM formulas were (123.8^1.22) × SD/(mean^1.22) in all participants, (119.9^1.12) × SD/ (mean^1.12) in 1765 untreated subjects, and (134.6^0.78) × SD/(mean^0.78) in 656 patients on antihypertensive drug treatment. For the evening blood pressure, the corresponding formulas were (121.7^1.15) × SD/(mean^1.15), (118.2^1.08) × SD/ (mean^1.08) and (131.1^0.73) × SD/(mean^0.73), respectively. Table 1 lists the baseline characteristics of the 2421 participants by sex-specific quartiles of VIM based on systolic blood pressure in the morning. The average morning blood pressure was similar across VIM quartiles (P=0.61), whereas the other indices of variability significantly increased with higher VIM (P<0.0001). These trends were similar across quartiles of VIM based on systolic blood pressure in the evening (Table S1 , available in the online-only Data Supplement). The proportion of participants on antihypertensive drug treatment increased (P<0.0001) from low to high VIM (Table 1 and Table S1 ). All of the indices of variability were significantly (P<0.0001) higher in 656 treated compared with 1765 untreated participants (Table S2 ). The morning and evening blood pressures were lower (P<0.0001) in women than in men R n X X n (Table S2 ). Although heart rate in women was similar to that in men (P=0.15), women had a significantly lower heart rate than men did in the evening (P<0.0001; Table S2 ). Coefficient of variation, VIM, and MMD were higher in women than in men in the morning (P≤0.0039), whereas in the evening these indices were similar in both sexes (P≥0.089; Table S2 ).
Incidence of Mortality and Morbidity
Over a median follow-up of 12.0 years (interquartile range, 9.9-15.4; maximum, 16.9 years), 412 participants died, 139 of cardiovascular causes (33.7%), and 223 stroke events occurred. All of the end points occurred at higher rates (P<0.0001) in treated compared with untreated participants (Table S3 ). Figure 1 shows the sex-and age-standardized rates across quartiles of the mean level and VIM of the morning systolic blood pressure. Total and cardiovascular mortality and stroke increased (P≤0.0004) with higher levels of mean blood pressure in the morning and evening. Total and cardiovascular mortality (P≤0.014) but not stroke (P=0.15) increased with higher morning VIM, whereas none of the studied end points was associated with evening VIM (P≥0.069). As shown by Kaplan-Meier survival estimates across quartiles of systolic blood pressure in the morning or evening, the mean level and VIM were consistent and significant (P<0.0001) predictors of cardiovascular mortality for all of the participants ( Figure 2 ).
Multivariable-Adjusted Analyses
Morning Blood Pressure
In multivariable-adjusted models ( Table 2) , the morning systolic blood pressure predicted total and cardiovascular mortality and stroke in all (P≤0.021) and untreated (P≤0.018) participants and stroke in patients on antihypertensive treatment (P=0.0008). In models including mean systolic blood pressure, VIM and ARV predicted total and cardiovascular mortality in all of the participants (P≤0.044). VIM also predicted total mortality in untreated participants (P=0.019) and cardiovascular mortality in treated patients (P=0.014). However, these indices did not predict any cardiovascular end point in untreated participants (P≥0.11). The R 2 statistics for adding morning VIM or ARV to models including mean blood pressure ( Table 2 ) ranged from 0.08% to 0.88%. MMD added to models including the morning systolic blood pressure did not predict future events ( Table 2 ; P≥0.085). Figure 3 shows the multivariable-adjusted 10-year risk of a cardiovascular death in relation to the mean level and VIM Values are number of participants (%) or arithmetic mean (SD). Blood pressure variability is based on self-measurement in the morning on 5 days within 1 hour after awakening and before taking antihypertensive medications in treated participants. Drinking status was unavailable in 608 participants. P denotes the significance of the linear trend across categories of systolic blood pressure level. *P<0.05, significance of the difference with the adjacent lower fourth. †P<0.0001, significance of the difference with the adjacent lower fourth. by guest on July 12, 2017 http://hyper.ahajournals.org/ Downloaded from of morning and evening systolic blood pressures in all of the participants. Figures S1 and S2 show similar information by treatment status. Morning systolic blood pressure was a consistent predictor of stroke and cardiovascular mortality (P≤0.0049) with the exception of cardiovascular mortality in treated participants (P=0.082).
Evening Blood Pressure
The evening systolic blood pressure predicted all of the end points (P≤0.044). In models already including the evening systolic blood pressure, VIM predicted cardiovascular mortality in all (P=0.014) and untreated (P=0.46) participants, whereas MMD and ARV did not significantly (P≥0.057) refine risk stratification ( Table 3 ). The R 2 statistics for adding evening VIM, MMD, or ARV to models including mean blood pressure ranged from <0.01% to 0.27% (Table 3 ).
Additional Analyses
The interaction terms between treatment status and the indices of variability were all not significant (P≥0.06). Results based on 5 home readings were confirmatory for morning (Table S4) and evening (Table S5 ) blood pressures.
Discussion
Our study addressed the incremental value of newly proposed indices 11 in the prediction of mortality and cardiovascular events over and beyond the blood pressure level. The key findings were as follows: (1) morning VIM and ARV, independent of blood pressure level, predicted total and cardiovascular mortality in all of the participants; (2) being treated with blood pressure-lowering drugs underlayed the predictive value of morning VIM; (3) in untreated participants, these indices of variability did not predict cardiovascular mortality; (4) none of the variability indices predicted stroke incidence; and (5) for all or cause-specific fatal combined with nonfatal outcomes, the incremental predictive value of VIM, MMD, and ARV over and beyond blood pressure level was tiny based on the viewpoint of R 2 statistics. These findings must be interpreted within the context of the overall available evidence.
To our knowledge, only 2 previous population studies 10,21 reported on the refinement of prognosis by considering variability of the self-measured blood pressure in addition to blood pressure level and other risk factors. In 2008, we assessed blood pressure variability from the self-measured blood pressure in the Ohasama population, using the within-subject SD of the morning systolic blood pressure over 26 days (median) of self-measurement. 10 Over 11.9 years of follow-up, 462 participants died, the underlying cause being cardiovascular in 168, noncardiovascular in 294, stroke in 83, and cardiac in 85 participants. 10 In multivariable-adjusted Cox models also including blood pressure level, a 1-SD increase in the between-subject variability was associated with higher risk of any death (hazard ratio, 1.18 [95% CI, 1.07-1.31]), cardiovascular death (hazard ratio, 1.20 [95% CI, 1.02-1.40]), noncardiovascular mortality (hazard ratio, 1.18 [95% CI, 1.04-1.34]), and stroke mortality (hazard ratio, 1.38 [95% CI, 1.12-1.72]) but not cardiac mortality hazard ratio (hazard ratio, 1.02 [95% CI, 0.89-1.29]). The association of blood pressure variability with noncardiovascular mortality was difficult to interpret but might reflect reverse causality, subclinical disease leading to greater variability. More recently, the Finn-Home investigators noticed 130 deaths and 179 cardiovascular events among 1866 Finns followed up for 7.8 years.
In multivariable-adjusted Cox models, day-to-day variability of the self-measured systolic blood pressure in the morning, estimated from the within-participant SD over 7 days, predicted total mortality and cardiovascular events. The hazard ratios expressing incremental risk for a 1-SD between-subject increment in variability (3.93 mm Hg) were ≈1.17 (95% CI, 1.00-1.30; P=0.03) and 1.21 (95% CI, 1.08-1.40; P=0.006), respectively. 21 Day-to-day variability in the evening systolic blood pressure was not predictive (P≥0.11). 21 Our current findings confirm that variability of the selfmeasured systolic blood pressure in the morning predicts total 10 and cardiovascular 10,21 mortality. In addition to being based on novel indices of blood pressure variability relatively independent of the mean, 7,11 our current report breaks new grounds in various ways. First, the previous Ohasama report 10 evaluated only fatal outcomes. In our current report, we demonstrated that neither morning nor evening blood pressure variability refined the risk stratification for fatal combined with nonfatal outcomes based on blood pressure level. In the Finn-Home study, 21 27) . Second, as in previous studies, 10,21 we adjusted for antihypertensive treatment in the whole study population. In addition, we also ran analyses stratified by treatment status, which showed that the association between cardiovascular mortality and morning blood pressure variability was in fact confined to patients on antihypertensive drug treatment. Third, cerebrovascular disease causes increased blood pressure variability by impairing baroreflexes 22 and interfering with the central regulation of blood pressure by the autonomous nervous system. To avoid confounding by reverse causality, we excluded patients with a history of stroke at enrollment. 23 Fourth, although the morning systolic blood pressure was an independent predictor of cardiovascular mortality, the incremental prognostic value over and beyond blood pressure level was small with R 2 statistics in the whole study population of ≤0.31% and ≤0.88% in the patients on antihypertensive drug treatment. Previous population studies 10,21 did not report R 2 statistics. Finally, Muntner et al 24 24 However, the P value for trend across these tertiles was marginal (0.064). Modeled as a continuous variable, blood pressure variability did not predict mortality. 24 Thus, although large epidemiologic studies might pick up incremental prognostic accuracy provided by blood pressure variability, this presumed risk factor remains weak and is unlikely to be clinically meaningful in individual subjects.
Events per 1000 subject years
A key finding in our current study was that morning blood pressure variability was a predictor of cardiovascular mortality in patients on antihypertensive drug treatment but was not prognostically informative in untreated participants. Redon et al 25 enrolled 15 618 hypertensive patients in an observational study. Patients recorded their blood pressure at home for 2 weeks. Blood pressure control was a self-measured blood pressure <135 mm Hg systolic and 85 mm Hg diastolic. At baseline (day 1 of the first week), control rates of the home blood pressure were 8.5%, 11.3%, and 9.9% in the morning, at lunchtime, and in the evening, respectively; at follow-up (day 4 of the second week), these rates were 31.8%, 42.2%, and 36.4%, respectively. In our current study, the systolic difference between morning and evening blood pressure averaged 2.15 mm Hg in the whole study population and 3.55 mm Hg in patients on antihypertensive drug treatment. Patients on treatment had to measure their blood pressure before taking their medication in the morning. In 1992, 21.3% of the Ohasama patients were on a once-daily treatment regimen, and 70.9% were taking nifedipine, nicardipine, or diltiazem in sustained-release formulations, 26 which have a duration of action of <12 hours. 27 To what extent these findings and the observations of Redon et al 25 explain why blood pressure variability was predictive in the morning, but not in the evening, remains to be elucidated. Rothwell et al 11 reported that amlodipine reduced visit-to-visit blood pressure variability partly by its long half-life. On the other hand, a meta-analysis by the same group, using interindividual variance as a surrogate for within-individual variability, put forward that calcium channel blockers reduced blood pressure variability independent of drug half-life. 12 The present study must be interpreted within the context of its potential limitations. First, our study population consisted of residents from a specific Japanese rural district. Although our results are in partial agreement with the Finn-Home study, 21 our current might not be generalizable to Western populations, in whom not stroke but myocardial infarction is the overriding cardiovascular complication associated with blood Systolic blood pressure (SBP) level and variability are based on self-measurement in the morning for median 26 days (interquartile range, 21-28) within 1 hour after awakening and before taking antihypertensive medications in treated participants. VIM, MMD, and ARV indicate variability independent of the mean, the difference between maximum and minimum blood pressure, and average real variability. CV indicates cardiovascular. The basic model accounts for sex, age, body mass index, heart rate, smoking and drinking, serum cholesterol, and diabetes mellitus, and history of CV disease. Full models include the aforementioned covariables and both mean SBP and an index of SBP variability. Hazard ratios (HRs) given with 95% confidence intervals (CIs) express the risk associated with a 1-SD increase in the explanatory variables: in all participants, 14.9 mm Hg for level of blood pressure and 2.9 units, 12.8 mm Hg, and 3.5 mm Hg for VIM, MMD, and ARV, respectively. The R 2 statistic is a measure for the risk prediction provided by the basic model including mean SBP and the additive contribution of the indexes of variability. *P<0.05, significance of the hazard ratios. †P<0.01, significance of the hazard ratios. ‡P<0.001, significance of the hazard ratios. §P<0.0001, significance of the hazard ratios.. pressure. In the Ohasama study, stroke caused 18.0% of total mortality, whereas in Finn-Home 21 this proportion was only 6.2%. Ischemic heart disease accounted for 7.1% and 22.3%, respectively. Second, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), 11 within-patient visit-to-visit variability was lower in the amlodipine than in the atenolol group among 19 257 randomized patients. The lower stroke risk in the amlodipine group (0.78 [95% CI, 0.67-0.90]) was partly attenuated by adjusting for mean systolic blood pressure during follow-up (0.84 [95% CI, 0.72-0.98]) and was diminished by also adjusting for VIM of clinic systolic blood pressure (0.96 [95% CI, 0.82-1.12]). 11 For coronary events, the ASCOT findings were similar. 11 In the current study, we only obtained detailed information on antihypertensive drug class in 366 treated patients, of whom 48.7% were taking calcium channel blockers and 17.5% β-blockers. In view of the incomplete information on drug class and the smaller sample size and observational nature of our current study, we could not stratify our analyses of 656 treated participants by drug class. Third, we based our main analyses on all of the available home blood pressure readings and only involved a single blood pressure reading in the morning and evening over a period of median 26 days. This is more than other European studies; for example, 5 consecutive home blood pressure readings in a European population study 16 and 7 days in the Finn-Home study. 6 Little information is currently available on how many days are required to capture blood pressure variability in a reliable way. However, sensitivity analyses making use of the home blood pressure over 5 days produced confirmatory results (Tables S3 and S4 ). Finally, the R 2 statistic is not a perfect measure of the variation explained by Cox models. R 2 values can be compared within but not across studies because of the dependence on censoring. Nevertheless, a measure of explained variance is crucial for the correct interpretation of the prognostic vale of a risk factor. P values of hazard ratios do not suffice to compare indicators of risk. 
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Perspectives
In the general population, blood pressure variability derived from home blood pressure does not substantially refine risk profiling over and beyond the blood pressure level. Being on antihypertensive drug treatment seems to be the main driver of the significant associations between cardiovascular mortality and blood pressure variability. Our findings also suggest, at variance with current guidelines, 1,3 that blood pressure variability, although showing up for selected fatal end points, might be too weak a predictor to be clinically meaningful.
In risk stratification, clinicians should concentrate on what really matters, that is, blood pressure level, the predominant modifiable risk factor, which is reversible by adequate medical treatment. Systolic blood pressure (SBP) level and variability are based on self-measurement for median 26 days (interquartile range, 22-28) before going to bed. VIM, MMD, and ARV indicate variability independent of the mean, the difference between maximum and minimum blood pressure, and average real variability. CV indicates cardiovascular. The basic model accounts for sex, age, body mass index, heart rate, smoking and drinking, serum cholesterol, and diabetes mellitus, and history of CV disease. Full models include the aforementioned covariables and both mean SBP and an index of SBP variability. Hazard ratios (HRs) given with 95% confidence interval (CIs) express the risk associated with a 1-SD increase in the explanatory variables: in all participants, 14.5 mm Hg for level of blood pressure and 2.8 units, 12.6 mm Hg, and 3.5 mm Hg for VIM, MMD, and ARV, respectively. The R 2 statistic is a measure for the risk prediction provided by the basic model including mean SBP and the additive contribution of the indices of variability. *P<0.05, significance of the hazard ratios. †P<0.01, significance of the hazard ratios. ‡P<0.001, significance of the hazard ratios. §P<0.0001, significance of the hazard ratios. 
Supplemental Results
Based on 5 home readings, for the morning blood pressure, the VIM formulas were (124.9^1.03) × SD/(mean^1.03) in all participants, (120.6^0.92) × SD/(mean^0.92) in 1765 untreated subjects, and (136.4^0.74) × SD/(mean^0.74) in 656 patients on antihypertensive drug treatment. For the evening blood pressure, the corresponding formulas were (122.7^0.99) × SD/(mean^0.99), (119.0^1.01) × SD/(mean^1.01), and (132.7^0.52) × SD/(mean^0.52), respectively.
Results based on 5 home readings were confirmatory for morning blood pressure (Table S4 ) as well as for the evening blood pressure (Table S5 ). Systolic blood pressure (SBP) level and variability are based on self-measurement on 5 days before going to bed. VIM, MMD and ARV indicate variability independent of the mean, the difference between maximum and minimum blood pressure and average real variability. CV indicates cardiovascular. The basic model accounts for sex, age, body mass index, heart rate, smoking and drinking, serum cholesterol, and diabetes mellitus, and history of CV disease. Full models include the aforementioned covariables and both mean SBP and an index of SBP variability. Hazard ratios (HRs) given with 95% confidence interval (CIs) express the risk associated with a 1-SD increase in the explanatory variables: in all participants, 15.4 mm Hg for level of blood pressure and 4.0 units, 10.5 mm Hg, 5.4 mm Hg for VIM, MMD and ARV, respectively. The R 2 statistic is a measure for the risk prediction provided by the basic model including mean SBP or the additive contribution of the indexes of variability. Significance of the hazard ratios: *P<0.05; †P<0.01; ‡P<0.001; and §P<0.0001. 140  160  100  120  140  160  100  120  140  160  100  120  140  160 
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